




RealRate

PHARMACEUTICAL 2024

Arrowhead Pharmaceuticals INC
Rank 165 of 309



The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 203%, being 10% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	419,521
Cost of Goods Sold	0
Intangible Assets	10,262
Liabilities, Current	105,456
Liabilities, Non-Current	372,934
Other Assets	45,507
Other Compr. Net Income	-3,086
Other Expenses	2,784
Other Liabilities	0
Other Net Income	-1,489
Other Revenues	240,735
Property and Equipment	290,262
Research and Development	353,188
Selling, General and Administrative Expense	92,549

Output Variable	Value in 1000 USD
Assets	765,552
Liabilities	478,390
Expenses	448,521
Revenues	240,735
Stockholders Equity	287,162
Net Income	-209,275
Comprehensive Net Income	-210,818
BaseVar	968,886
ECR before LimitedLiability	67%
Economic Capital Ratio	203%